Cargando…

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

OBJECTIVE: Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it remains unclear whether other tauopathies induce pT217 modifications. To d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Chihiro, Mallipeddi, Nipun, Ghoshal, Nupur, Wright, Brenton A., Day, Gregory S., Davis, Albert A., Kim, Albert H., Zipfel, Gregory J., Bateman, Randall J., Gabelle, Audrey, Barthélemy, Nicolas R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419397/ https://www.ncbi.nlm.nih.gov/pubmed/34342183 http://dx.doi.org/10.1002/acn3.51435

Ejemplares similares

Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer’s Disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2019)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain
por: Horie, Kanta, et al.
Publicado: (2020)

Evidence for a Common Founder and Clinical Characteristics of Japanese Families with the MAPT R406W Mutation
por: Ikeuchi, Takeshi, et al.
Publicado: (2011)

Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum
por: Gossye, Helena, et al.
Publicado: (2022)

CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
por: Horie, Kanta, et al.
Publicado: (2022)

Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review
por: Ygland, Emil, et al.
Publicado: (2018)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels
por: Wennström, Malin, et al.
Publicado: (2022)

Young‐onset frontotemporal dementia in a homozygous tau R406W mutation carrier
por: Ng, Adeline S. L., et al.
Publicado: (2015)

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

Tau Isoforms: Gaining Insight into MAPT Alternative Splicing
por: Corsi, Andrea, et al.
Publicado: (2022)

Chronic GCPII (glutamate‐carboxypeptidase‐II) inhibition reduces pT217Tau levels in the entorhinal and dorsolateral prefrontal cortices of aged macaques
por: Bathla, Shveta, et al.
Publicado: (2023)

The frontotemporal dementia mutation R406W blocks tau’s interaction with the membrane in an annexin A2–dependent manner
por: Gauthier-Kemper, Anne, et al.
Publicado: (2011)

Pathological Progression Induced by the Frontotemporal Dementia-Associated R406W Tau Mutation in Patient-Derived iPSCs
por: Nakamura, Mari, et al.
Publicado: (2019)

Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease
por: Coupland, Kirsten G., et al.
Publicado: (2016)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

Granulovacuolar degeneration bodies: red alert for neurons with MAPT/tau pathology
por: Wiersma, Vera I., et al.
Publicado: (2019)

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
por: Ashton, Nicholas J., et al.
Publicado: (2022)

Memorandum: Experiment R406
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1974)

R406 - control room
por: CERN PhotoLab
Publicado: (1975)

Kainic acid hyperphosphorylates tau via inflammasome activation in MAPT transgenic mice
por: Zheng, Xiang-Yu, et al.
Publicado: (2019)

Evolutionary perspective of Big tau structure: 4a exon variants of MAPT
por: Fischer, Itzhak
Publicado: (2022)

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios
por: Janelidze, Shorena, et al.
Publicado: (2023)

(18)F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers
por: Smith, Ruben, et al.
Publicado: (2016)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study
por: Plowey, Edward D., et al.
Publicado: (2016)

In vitro Tau Aggregation Inducer Molecules Influence the Effects of MAPT Mutations on Aggregation Dynamics
por: Ingham, David J., et al.
Publicado: (2022)

Mitotic phosphorylation of Tau/MAPT modulates cell cycle progression in prostate cancer cells
por: Clementi, Letizia, et al.
Publicado: (2023)

Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
por: Lantero-Rodriguez, Juan, et al.
Publicado: (2023)

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease
por: Janelidze, Shorena, et al.
Publicado: (2020)

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays
por: Leuzy, Antoine, et al.
Publicado: (2021)

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
por: Mattsson-Carlgren, Niklas, et al.
Publicado: (2020)

Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue
por: Tauber, Christina V., et al.
Publicado: (2023)

Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration
por: Giannini, Lucia A. A., et al.
Publicado: (2022)

Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response
por: Callari, Maurizio, et al.
Publicado: (2023)

Tau/MAPT disease-associated variant A152T alters tau function and toxicity via impaired retrograde axonal transport
por: Butler, Victoria J, et al.
Publicado: (2019)

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells
por: Ikeda, Hirokuni, et al.
Publicado: (2010)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q2hq3bfb96k1rq2ge1rncnuu30